A Novel Signature Based on mTORC1 Pathway in Hepatocellular Carcinoma

Table 1

Baseline patient characteristic in TCGA, GEO, and ICGC cohorts.

Clinical characteristics		Number	Percent (%)
TCGA-LIHC (n = 377)
Survival status	Survival	249	66
	Death	128	34
Age (1 patient missing)	≤65 years	235	62.5
	>65 years	141	37.5
Gender	Female	122	68
	Male	255	32
Stage (24 patients missing)	I	175	50
	II	87	24.6
	III	86	24.4
	IV	5	1
Grade (5 patients missing)	G1	55	14
	G2	180	48
	G3	124	33
	G4	13	5
T classification (3 patients missing)	T1	185	49
	T2	95	26
	T3	81	22
	T4	13	3
GSE76427 (n = 115)
Survival status	Survival	92	80
	Death	23	20
Age	≤65 years	65	56.5
	>65 years	50	43.5
Gender	Female	22	19.1
	Male	93	80.9
Stage	I	55	47.8
	II	35	30.4
	III	21	18.3
	IV	4	3.5
ICGC-LIRI (n = 260)
Survival status	Survival	214	82.4
	Death	46	17.6
Age	≤65 years	98	37.7
	>65 years	162	62.3
Stage	I	40	15.4
	II	117	45
	III	80	30.8
	IV	23	8.8